This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
healthcare: Archive
Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run?
by Urmimala Biswas
Tempus AI rallies in 2025, but a Hold rank and mixed style scores argue for patience until pricing, FDA, and MRD milestones firm up.
IQVPositive Net Change GHPositive Net Change TEMPositive Net Change
artificial-intelligence earnings-report healthcare medical medical-devices valuation
Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook
by Urmimala Biswas
Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner.
ILMNPositive Net Change GHPositive Net Change TEMPositive Net Change
artificial-intelligence earnings-report healthcare medical medical-devices
Tempus AI: Revenue Mix and 2026 Growth Outlook Explained
by Urmimala Biswas
Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.
EXASPositive Net Change GHPositive Net Change TEMPositive Net Change
healthcare medical medical-devices oncology-screening
Is UnitedHealth's Valuation Dip & Divestment Diet a Real Buy Window?
by Kaibalya Pravo Dey
UNH trades below its five-year median P/E as it navigates margin pressure, membership declines and strategic divestments.
UNHPositive Net Change HUMPositive Net Change ELVPositive Net Change
healthcare hmo insurance insurance-premium medical
Battle of Benefits: Will UNH Deliver the Bigger Dose or CVS? (Revised)
by Rajshree Sipani
CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.
UNHPositive Net Change CVSPositive Net Change
healthcare hmo insurance medical smart-health
Battle of Benefits: Will UNH Deliver the Bigger Dose or CVH?
by Rajshree Sipani
CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.
UNHPositive Net Change CVSPositive Net Change
healthcare hmo insurance medical smart-health
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
by Urmimala Biswas
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
BSXPositive Net Change AMGNPositive Net Change EWNegative Net Change OHIPositive Net Change ABBVNegative Net Change CTREPositive Net Change ENSGPositive Net Change
biotechs cell-therapy gene-therapy genetics genomics healthcare hospitals medical medical-devices
UnitedHealth Recovers Its Rhythm Before Q3 Earnings: Time to Buy?
by Kaibalya Pravo Dey
UNH's Q3 results hinge on premium growth and Optum gains amid rising costs and margin pressure.
UNHPositive Net Change HUMPositive Net Change MOHNegative Net Change
earnings-outlook earnings-preview healthcare hmo insurance insurance-premium medical
UNH vs. HUM: Which Healthcare Stock is the Healthier Buy Now?
by Kaibalya Pravo Dey
Humana's sharper Medicare focus, cost discipline and leaner structure position it ahead of UnitedHealth in the healthcare stock race.
UNHPositive Net Change HUMPositive Net Change
healthcare hmo insurance medical
Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains
by Urmimala Biswas
Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.
ABTPositive Net Change BSXPositive Net Change MDTNegative Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical medical-devices